Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research

Rebecca C Fitzgerald,1,2,3 Richard Hardwick,4 David Huntsman,5 Fatima Carneiro,6 Parry Guilford,7 Vanessa Blair,7 Daniel C Chung,8 Jeff Norton,9 Krishnadath Ragunath,10 J Han Van Krieken,11 Sarah Dwerryhouse,12 Carlos Caldas,3,13 on behalf of the International Gastric Cancer Linkage Consortium

ABSTRACT
25–30% of families fulfilling the criteria for hereditary diffuse gastric cancer have germline mutations of the CDH1 (E-cadherin) gene. In light of new data and advancement of technologies, a multidisciplinary workshop was convened to discuss genetic testing, surgery, endoscopy and pathology reporting. The updated recommendations include broadening of CDH1 testing criteria such that: histological confirmation of diffuse gastric cancer is only required for one family member; inclusion of individuals with diffuse gastric cancer before the age of 40 years without a family history; and inclusion of individuals and families with diagnoses of both diffuse gastric cancer (including one before the age of 50 years) and lobular breast cancer. Testing is considered appropriate from the age of consent following counselling and discussion with a multidisciplinary team. In addition to direct sequencing, large genomic rearrangements should be sought. Annual mammography and breast MRI from the age of 35 years is recommended for women due to the increased risk for lobular breast cancer. In mutation positive individuals prophylactic total gastrectomy at a centre of excellence should be strongly considered. Protocolised endoscopic surveillance in centres with endoscopists and pathologists experienced with these patients is recommended for: those opting not to have gastrectomy, those with mutations of undetermined significance, and in those families for whom no germline mutation is yet identified. The systematic histological study of prophylactic gastrectomies almost universally shows pre-invasive lesions including in situ signet ring carcinoma with pagetoid spread of signet ring cells. Expert histopathological confirmation of these early lesions is recommended.

OVERVIEW
Gastric cancer is the fourth most common cause of cancer worldwide; by 2030 deaths from gastric cancer globally are predicted to have risen from the 15th to the 10th leading cause of mortality from all causes.1 The vast majority of gastric cancers are sporadic, although it has now been established that 1–5% of gastric cancers arise as a result of inherited gastric cancer predisposition syndromes2–4 Inherited gastric cancers are more commonly of the diffuse type or linitis plastica and are generally referred to as hereditary diffuse gastric cancer (HDGC). In order for a family to qualify for a diagnosis of HDGC the following criteria have been used5 6: 1. Two or more documented cases of diffuse gastric cancer in first or second degree relatives, with at least one diagnosed before the age of 50, or 2. Three or more cases of documented diffuse gastric cancer in first/second degree relatives, independent of age of onset. Over 10 years ago linkage analysis implicated germline mutations of the tumour suppressor gene E-cadherin (CDH1) as the genetic cause of HDGC.7 Shortly afterwards it was estimated that about 25% of families fulfilling the clinical criteria for HDGC would have inactivating CDH1 germline mutations.5 The trigger and molecular mechanism by which the second allele of E-cadherin is subsequently inactivated appears to be diverse and includes methylation, mutation and loss of heterozygosity (LOH).8 Published data from these families suggest that the penetrance of CDH1 gene mutations is high,9 with an estimated risk of >80% (analysis updated in 2008, unpublished data). In other words, carriage of the abnormal E-cadherin gene confers more than an 80% lifetime risk of developing gastric cancer. The causal germline mutations accounting for HDGC cases without an identified defect in CDH1 are currently unknown.

Increasing awareness of HDGC and the rapid advances in genetic diagnostic tools, endoscopic modalities and the increasing use of laparoscopic surgery led a group of clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists and molecular biologists from nine different countries to convene a workshop in order to update the management guidelines for this condition originally set in 1999 and to propose directions for future research. The workshop discussions were focused on four major topics: (1) genetic counselling and testing; (2) endoscopic surveillance of the stomach and screening for other cancers; (3) prophylactic gastrectomy; and (4) pathological specimen processing and diagnosis.

GENETIC COUNSELLING AND TESTING
Genetic counselling is an essential component of the evaluation and management of HDGC. The genetic evaluation should include a careful three-generation family pedigree, histopathological confirmation of diffuse gastric cancer diagnoses or
precursor lesions, a discussion of lifetime risks of diffuse gastric cancer (updated to >80% in both men and women by age 80) and lobular breast cancer (updated to 60% in women by age 80), and current CDH1 mutation detection rates (25–50%). Informed consent for genetic testing is required. The counselling process should include not only a formal genetics evaluation but also the input from a multidisciplinary team (MDT) comprising those with relevant expertise in gastric surgery, gastroenterology, pathology, and nutrition. Ideally, the full team should be engaged in both the pre-genetic testing and post-genetic testing phases, but MDT involvement is mandatory in the post-test setting.

Genetic testing should be initiated in an affected proband. The recommended youngest age at which to offer testing to relatives at risk is not well established. Rare cases of clinically significant diffuse gastric cancer have been reported in affected families before the age of 18, but the overall risk of diffuse gastric cancer before the age of 20 is very low. It was agreed that consideration of genetic testing can begin at the age of consent (16/18 years), but that the testing of family members under 18 years should consider the earliest age of cancer onset in HDGC families from the local population and the psychological, emotional, and physical health of the individual and their family. For example, in New Zealand, CDH1 mutation carriers have developed gastric cancer in their mid-teens; as a consequence, genetic testing begins at 16 years of age, and occasionally 1–2 years before, on a case by case basis.

While the workshop endorsed the clinical definition of hereditary diffuse gastric cancer established in 1999, the criteria for which are stated above, they also recommended a broader set of clinical criteria as indications for genetic testing for CDH1 mutations: namely, relaxation of the restriction for histopathological confirmation of diffuse gastric criteria to one family member, inclusion of individuals with diffuse gastric cancer before the age of 40 years without a family history, and inclusion of individuals and families with diagnoses of both diffuse gastric cancer (including one case below the age of 50 years) and lobular breast cancer (figure 1). In addition, in cases where expert pathologists detect in situ signet ring cells and/or pagetoid spread of signet ring cells adjacent to diffuse type gastric cancer, genetic testing should be considered since this is rarely if ever seen in sporadic cases.

In previous studies the detection rate of CDH1 mutations was reported to be 25–50% when the following criteria were used for inclusion: histologically confirmed diffuse gastric cancer in three first degree family members at any age, or two or more gastric cancers in first degree relatives with at least one confirmed diffuse gastric cancer diagnosed before age 50. Importantly, 4% of these mutation positive families exhibited large germline deletions of CDH1 that were not detectable by conventional DNA sequencing. Genetic testing on blood for germline mutations should be performed in Clinical Laboratory Improvement Amendments (CLIA) approved molecular diagnostic laboratories or research laboratories with expertise in CDH1 gene analysis. Analysis of large genomic deletions with multiplex ligation independent probe amplification (MLPA) or alternative methods (array comparative genomic hybridisation (CGH)) is recommended in cases where DNA sequencing is unrevealing. When blood is not available consideration should be given to testing DNA from paraffin, although any results

Figure 1 Algorithm for management starting from clinical criteria, genetic testing, role of endoscopy and gastrectomy. EGD, oesophagogastroduodenoscopy; MLPA, multiplex ligation dependent probe amplification.
from this material need to be treated cautiously and rigorously confirmed (figure 2).

By genetic criteria, any family with a germline CDH1 mutation would comprise an HDGC kindred. It is critical that families who meet clinical criteria for HDGC, but do not carry an identifiable CDH1 mutation or who carry a CDH1 variant that does not result in a truncated protein, are registered for clinical research studies. Whenever possible, it is important to define the pathogenicity of CDH1 variants including missense alterations, and the following terminology should be used to classify these variants: silent polymorphism, variant of uncertain significance, likely deleterious variant.\(^\text{16–20}\) Assessment of pathogenicity of such missense mutations relies on in vitro assays of E-cadherin dependent cellular aggregation and invasion or in silico analyses that predict alterations in E-cadherin protein function based upon conserved evolutionary motifs.\(^\text{18}\) Furthermore, it is likely that there are additional genetic loci independent of CDH1 that confer an increased risk of diffuse gastric cancer, and careful identification and characterisation of such diffuse gastric cancer families without known pathogenic CDH1 mutations is a prerequisite to defining these loci.

Endoscopic assessment for gastric cancer in individuals with a germline CDH1 mutation is described in detail under ‘Endoscopic surveillance’. The management for those with clinical features suggestive of HDGC but without a germline CDH1 mutation is not straightforward. We would recommend that intensive endoscopic surveillance should also be offered to families who fulfil the revised criteria as set out in figure 1. With the increasing evidence for a risk of lobular breast cancer for females who carry pathogenic CDH1 mutations, it was recommended that enhanced breast cancer screening should be strongly considered. There are currently insufficient data on the role and outcome of breast cancer screening in this population, but the high lifetime risk of breast cancer, particularly the lobular subtype, and the precedents established in other hereditary breast cancer syndromes establish a rationale. Referral to a high risk breast clinic is recommended. For those who choose to undergo screening, we recommend monthly breast self examinations starting at age 35, annual mammogram and breast MRI, and a biannual clinical breast examination. The age of 35 is a pragmatic choice but accurate age related penetrance for breast cancer data is needed in order to confirm the age at which screening should be commenced. In the meantime, in view of the current lack of evidence, breast screening should be carried out in the context of a research protocol as this may permit the formulation of evidence based guidelines in the future. Prophylactic mastectomy cannot be uniformly recommended, but it may be a reasonable option for some women. There are insufficient data to recommend chemoprevention with tamoxifen.

There is also emerging evidence for an increased risk of colon cancer in HDGC families, and these colon cancers can display signet ring cell features (D Huntsman, P Pharoah, personal communications 2009). In CDH1 families in which colon cancer is reported, information should be collected concerning the age at diagnosis, whether the affected member(s) are first or second degree relatives, and whether the pathology was mucinous or showed signet ring cells. Depending on these factors, enhanced screening should be considered with colonoscopy beginning at age 40 or 10 years younger than the youngest diagnosis of colon cancer, whichever is younger, and repeated at intervals of 5–8 years. It is imperative that data on colonoscopic screening in these individuals are collated so that these guidelines can be evidenced based in the future.

ENDOSCOPIC SCREENING AND SURVEILLANCE

To clarify the terminology, individuals having endoscopy who do not have a CDH1 mutation are having screening, whereas mutation positive individuals are undergoing surveillance. The consensus reached at the workshop was that individuals who tested positive for a CDH1 mutation should be advised to consider prophylactic gastrectomy regardless of any endoscopic findings. However, the timing of this operation may vary according to the preferences and age as well as the physical and psychological fitness of the individual. In patients going forward for gastrectomy a baseline endoscopy should be performed before surgery to look for macroscopic tumour and in order to inform the data on endoscopic detection of microscopic lesions. The information on microscopic disease foci is useful to compare with findings in the surgical resection specimen and hence to inform the data on the likelihood of endoscopic detection of microscopic lesions. For individuals in whom gastrectomy is not currently being pursued (eg, through patient choice), annual endoscopy should be offered in order to ensure that there is no evidence of clinically significant lesions and for research purposes (assuming ethical approval) in order to help understand the natural history of early lesions. Similarly, if the CDH1 positive individual declines gastrectomy then endoscopic surveillance should be offered under a research protocol. In these individuals surveillance can have the advantage of helping them to come to a decision about the need for gastrectomy, since when microscopic foci of signet ring cells are detected this can help the individual confront their risks from this mutation. For those individuals with mutations of undetermined significance (eg, missense), or in those in whom no mutation can be identified in the index case, then endoscopy has a useful role to play in guiding clinical decision making. Specifically, any malignant lesions detected endoscopically would prompt a referral for gastrectomy. However, all patients should be counselled that in view of the very focal nature of these endoscopically invisible lesions it is quite possible that they will not be detected by random biopsies (figure 1).

ENDOSCOPY PROTOCOL

Individuals should be offered an annual endoscopy that should ideally be performed in a centre with a special interest in, and

---

**Figure 2**  Germline deletions in CDH1. The CDH1 and CDH3 genes are shown in grey with the exons for CDH1 indicated. The red areas indicate five deletions detected by multiplex ligation dependent probe amplification.
experience with this condition. The endoscopy should be performed using a white light high definition endoscope in a dedicated session with at least 30 min allocated to allow for a careful inspection of the mucosa on inflation and deflation, and to allow time for multiple biopsies to be taken. Use of mucolytics such as acetylcysteine may be helpful to obtain good views.

Although there does not appear to be an association between Helicobacter pylori infection and HDGC, it is important to test for H pylori to document the prevalence of infection in mutation carriers. Furthermore, since H pylori is a World Health Organization class 1 carcinogen it is agreed that when individuals are infected it should be eradicated.

Due to the tiny microscopic foci of signet ring cells multiple biopsies are required to maximise the likelihood of diagnosing them.21 Targeted biopsying of the body—antral transitional zone of the stomach during endoscopic surveillance has been suggested to increase the diagnostic yield on the basis that in New Zealand Maori families, a predilection was observed for early invasive carcinomas to occur in this area of the stomach.12 22 In North American and European families, early invasive carcinoma was identified from the cardia to pre-pyloric region, without evidence of antral clustering.21 24–26 In a case series reported by Rogers et al.,27 70% of the total foci were localised in the proximal third of the stomach. In a series from the UK21 the highest number of foci were again observed in the fundus (44.7%) followed by the body (40.2%). Reasons for the different anatomical localisation of the cancer foci in the aforementioned studies remain to be clarified, but may include environmental factors or differences in the molecular pathogenesis. Therefore it is recommended that any endoscopically visible lesions are targeted and that in addition random sampling of six biopsies is taken for each of the following anatomical zones: antrum, transitional zone, body, fundus, cardia. In all a minimum of 30 biopsies are recommended and a suggested protocol is given in supplementary figure 1.

Chromoendoscopy was initially trialled with Congo red and methylene blue28; however, concerns over the toxicity of Congo red mean that this stain is no longer recommended. Other chromoendoscopic techniques are currently not recommended except in the research setting. Endoscopic technologies are advancing rapidly and the use of trimodal imaging, confocal endomicroscopy and molecular imaging techniques need to be explored (eg, Dunbar and Canto, 200929).

In order to maximise the yield from endoscopy, specialist histopathology reporting is essential and the guidelines outlined in the pathology section below should be followed.

**PROPHYLACTIC GASTRECTOMY**

**Indications for and timing of surgery**

As discussed above, since the penetrance of HDGC is >80%, and since endoscopic surveillance and analysis of gastrectomy specimens suggests that microscopic foci of signet ring cells are almost universally present in mutation carriers (see section entitled Pathology: Classification of microscopic foci and determination of significance), surgery should be strongly considered whenever an at risk family member is found to have a CDH1 mutation as discussed above. However, the timing of the gastrectomy is debatable. The evidence increasingly suggests that there is likely to be a dormant period in which the signet ring cell adenocarcinoma does not spread or progress since they have a low proliferative index.8 This may explain why so many individuals are found to have T1 N0 stage tumours after prophylactic gastrectomy.30 However, with our current lack of knowledge of the behaviour of mucosal signet ring cancer cells, it is recommended that if they are detected on endoscopic biopsies the patient should be advised to undergo a total gastrectomy regardless of age, although it is rare that endoscopy would be recommended before 16 years. CDH1 mutation positive patients with normal gastric biopsies should be advised to undergo gastrectomy once the genetic testing results are known and once individuals are older than 20 years.12 Patients under the age of 40 who develop symptomatic invasive diffuse gastric carcinoma have a poor prognosis with as few as 10% having early and curable disease.31 As our understanding of the natural history of mucosal signet ring cancer in HDGC improves it may be possible to safely leave some patients until they are older, but until that time it is safer to recommend surgery early in adult life. This has implications for the long term follow-up of prophylactic gastrectomy patients, especially women who are more at risk of iron deficiency anaemia and osteoporosis than men, and re-enforces the need for multidisciplinary teams to care for these patients.

Prophylactic gastrectomy is clearly a significant undertaking. The decision as to if and when to proceed will therefore be influenced by the psychological and physical fitness of the individual and their occupation and other family commitments. Therefore, a multidisciplinary approach to preoperative counselling involving a gastroenterologist, surgeon, dietician, genetic counsellor and specialist nurse is absolutely necessary. This team should work in a high volume cancer centre with low peri-operative mortality rates,32 (<1% for fit patients undergoing total gastrectomy33). There are now reports to show that pregnancy can be carried to full term following a prophylactic gastrectomy (manuscript submitted) and individuals are able to return to full time work including manual workers. Despite this, the physiological, metabolic and emotional impact of removing a young adults stomach should not be underestimated.

**Operation details**

The requisite operation is a total gastrectomy with Roux-en-Y reconstruction, ensuring that the jejuno-jejunostomy anastomosis is at least 50 cm distal to the oesophago-gastric anastomosis to reduce the risk of biliary reflux. The proximal resection line must be across the distal oesophagus to ensure that no gastric cardia mucosa is left behind. There is no need for a radical lymph node dissection in the prophylactic setting since mucosal adenocarcinoma without submucosal invasion has a very low risk indeed of lymph node metastases.34 In view of this, a vagal sparing resection is possible and there are good theoretical reasons why this might give an improved quality of life for patients compared to those undergoing a truncal vagotomy as a byproduct of their gastrectomy.35 36 Studies are needed to assess the benefits of this strategy and this group of patients provide a unique population in which to study various aspects of surgical reconstruction such as the provision of a pouch. At the current time, although preliminary studies from Germany and Japan suggest that a pouch may afford an improved quality of life,37 this requires further study and the surgeon should continue to do what he or she is most familiar with. This applies also to whether the preferred surgical approach is open or laparoscopic. Some teams have made good progress at safely introducing a minimally invasive approach to gastric cancer surgery,38 39 but any surgeon proposing to do a prophylactic gastrectomy laparoscopically must be able to reassure the patient with audited data that this is without additional risk. These operations are not suitable to be done during a surgeons ‘laparoscopic learning curve’. It may also be very helpful for patients to have a chance to talk to other individuals who have been through the same operation to
help them make an informed decision and they know what
to expect.

The major issues that worry patients are related to the
morbidity and mortality of the gastric cancer compared to that
of total gastrectomy. The short term and long term morbidity
and mortality of total gastrectomy in these patients does need
to be carefully audited. For example, although a prophylactic
gastrectomy may improve quality of life as a result of a reduc-
tion of the anxiety about stomach cancer, it may worsen
because of the side effects associated with the procedure.
Following a prophylactic gastrectomy patients have to eat
little and often and require support from a dietician. Eating
too much too quickly will cause abdominal pain. Dumping
syndrome can be troublesome and causes a range of symptoms
including pain, nausea, tiredness after eating and diarrhoea.
Other problems may include: lactose intolerance, fat malab-
sorption and steatorrhoea, bacterial overgrowth, and post-
prandial fullness.40–41 Each patient is different after their
surgery and it is impossible to predict how affected they will
be, but all of them will lose weight and require lifelong
vitamin B12injections and close monitoring for conditions such
as anaemia and trace element deficiencies. For most patients,
any negative consequences of surgery slowly improve over
the first year. Physical function normally returns to normal
by 6 months.

The severity and longevity of complications in previously fit
young individuals following gastrectomy has not been evaluated
and this is an area that requires further research. A central
registry of families and patients treated surgically would be very
helpful to collect data prospectively on the physical and
psychological effects of surgery and improve the care given to
patients in the future. One such registry is currently coordinated
in Cambridge, UK.

**PATHOLOGY: CLASSIFICATION OF MICROSCOPIC FOCI AND
DETERMINATION OF SIGNIFICANCE**

Currently, there is information available from 96 total gastrec-
tomies in the setting of HDGC, corresponding to published
reports,12 13 21–28 38 42–47 and unpublished observations. These
96 gastrectomies encompass two groups: (1) 73 correspond to
real prophylactic gastrectomies (those performed in CDH1
mutation carriers who had negative biopsies before surgery); (2)
the remaining 23 correspond to total gastrectomies performed in
patients in whom early invasive cancer had been identified in
preoperative endoscopic biopsies. In the former (real prophyl-
lactic gastrectomies), 42 were studied under a research protocol
and early invasive signet ring cell carcinoma was identified in 39
cases (95%). In two out of the three cases in which early invasive
carcinoma were not identified, tiny foci of in situ signet ring cell
carcinoma were observed (unpublished observations). In the 31
prophylactic gastrectomies whose study was not performed
under a research protocol, early invasive signet ring cell carcino-
ma was identified in 25 cases (81%). Concerning the total
gastrectomies performed after the preoperative identification of
early invasive cancer, all specimens exhibited intramucosal
signet ring cell carcinoma (one or more foci).

The need for a systematic study of these prophylactic speci-
mens is highlighted by the case reported by Gaya et al in which
histopathology was initially reported to be negative,48 and
which was later submitted to a detailed analysis according to
a research protocol. This research analysis led to the identifica-
tion of four foci positive for early invasive carcinoma.49 Similar
findings had been previously reported by Lewis et al.25

Taken together these systematic studies of prophylactic
gastrectomies have led to the proposal of a model for the
development of diffuse gastric cancer in germline CDH1 dele-
terious mutations carriers which encompasses, as pre-invasive
lesions, in situ signet ring carcinoma with pagetoid spread of
signet ring cells. The discrepancy between the numerous T1a
carcinoma foci and the low number of in situ carcinoma lesions
suggests that invasion of the lamina propria by signet ring cells
may occur without a morphologically detectable in situ carci-
noma.23 50

Special attention should be paid to the two precursor lesions
of early invasive signet ring cell carcinoma: (1) in situ signet ring
cell carcinoma, corresponding to the presence of signet ring cells
within the basal membrane, generally with hyperchromatic and
depolarised nuclei; (2) pagetoid spread of signet ring cells below
the preserved epithelium of glands and foveolae (figure 3).
Criteria for the identification of these lesions should be strictly
followed in order to diminish the risk of over diagnosing non-
specific changes and distinguishing from lesions that mimic
signet ring cells.51–53 Therefore, confirmation of these lesions by
an independent histopathologist with experience in this area is
strongly recommended.

Background changes in the gastric mucosa of prophylactic
gastrectomy specimens encompass mild chronic gastritis, some-
times displaying the features of lymphocytic gastritis. Occa-
sionally, an inflammatory granulomatous reaction is observed at
the periphery of some collapsing glands. Follicular hyperplasia
and tufting of surface epithelium, focally with gobletoid change,
is also a frequent finding and, in some areas, vacuolisation
of surface epithelium is very striking4 23 50 (figure 4).

Additionally, erosions and cysts may be found in non-
neoplastic mucosa. In most prophylactic gastrectomies reported
so far, intestinal metaplasia and H pylori infection are absent
(families from North America and Europe). The exceptions are
two cases from New Zealand in which H pylori infection was
identified before surgery (several months or years) and a
gastrectomy performed in a Portuguese patient (unpublished).

An unsolved issue is the distribution of early lesions of HDGC
in the stomach, as discussed above. Therefore it is essential that
the location of biopsies and the positive regions within gastrectomy
specimens are specifically reported. Additionally, a critical
question that remains unanswered is how long early lesions of
HDGC can remain indolent until there is emergence of clinical
disease that may be rapidly progressive and lethal. Continuing
collection of data is essential to help answer these ques-
tions—for example, in the rare individuals who opt for endo-
scopic surveillance until such time as invasive carcinoma is
documented, as discussed above.

**REPORTING OF GASTRECTOMY SPECIMENS**

Macroscopic observation and sampling of prophylactic gastrec-
tomies should follow specific protocols. Fresh gastrectomy speci-
mens should be opened along the greater curve (after painting
the margins, dissection of the omentum and retrieval of lymph
nodes) and pinned onto a cork board. A life size specimen photo
should be used as a template to identify the exact location of the
tissue blocks (a schematic map/diagram can be used for that
purpose) (figure 5). The possibility of collecting and snap freezing
fresh tissue samples from any macroscopic lesion and normal
looking mucosa (lesser and greater curvatures, anterior and
posterior walls of the stomach) for research purposes should be
considered. Overnight fixation in buffered formalin is recom-
manded before sampling for routine histopathology, including
any macroscopically abnormal areas including pale lesions. Sections of the margins should be taken (and labelled) and the remainder of the stomach should be sectioned completely (each section 2 cm×0.5 cm, full thickness) and blocked (paraffin embedded). This usually results in between 100–500 blocks per stomach. The precise location of each section should be marked on the map of the stomach. In case gross lesions are found, these should be precisely localised within the map.

The histological examination should be made using a checklist focusing on the following issues (see supplementary figure 2): (1) features of invasive (intramucosal) carcinoma(s), such as anatomical site (cardia, fundus, body, transitional zone, antrum), location (greater curvature, lesser curvature, anterior wall, posterior wall, circumferential), histological type (WHO, Laurén’s classifications, lymphatic, venous and neural invasion (present or absent), precursor lesions such as in situ carcinoma and pagetoid spread (present or absent), status of surgical margins, stromal reaction (lymphocytic infiltrates, eosinophilia, desmoplasia and granulomatous reaction); (2) general features of non-neoplastic mucosa (chronic inflammation, activity, H pylori microorganisms, intraepithelial lymphocytes, intestinal metaplasia, dysplasia); (3) specific features of non-neoplastic mucosa (hyperplastic changes, tufting of surface epithelium, vacuolisation of surface/foveolar epithelium, ulcers, erosions, granulomas, cysts). In case the final report is presented in the format of a checklist, a summary should be presented at the end.

In case of restricted time available due to the pathologist’s workload and lab resourcing, and sometimes requests from the patients for return of gross specimens, it is not possible to perform a full embedding of the stomach on a routine basis. In such cases the minimum examination of a macroscopically normal gastrectomy should include:

1. Proximal and distal margins to confirm if the gastric mucosa has been resected.
2. All lymph nodes should be sampled as per a usual gastrectomy.
3. Photograph.
4.Mapped sampling from all zones; antrum, transitional zone (angularis incisura), body and fundus.
5. If no foci of carcinoma are found, then to go back to the specimen and take more blocks. Step 4 repeated as time, workload and resourcing allow.

The report should follow the checklist in supplementary figure 2. In the event of not finding foci of signet ring cell carcinoma, the gastrectomy should not be reported as negative for carcinoma, but as ‘no carcinoma found in xx% of mucosa examined’.

USE OF IMMUNOSTAINING AND HISTOCHEMICAL STAINS

Diffuse or signet ring cell carcinomas are easily detected on Haematoxylin and eosin (H&E) sections. The use of histochemical stains for neutral mucins, such as periodic acid-Schiff (PAS) and diastase digestion, may be useful for the detection or confirmation of tiny intramucosal carcinomas in which the neoplastic cells are dispersed among preserved foveolae and glands. E-cadherin immunoeexpression has been shown to be reduced or absent in early invasive gastric carcinomas, contrasting with the normal membranous E-cadherin expression in adjacent non-neoplastic mucosa, in keeping with a clonal origin of the cancer foci. In pagetoid spread lesions and in situ carcinomas E-cadherin immunoexpression was also shown to be reduced or absent. However, one should be aware that E-cadherin expression is not always reduced or absent, depending on the mutation localisation and specific mechanisms of inactivation of the wild type allele.

CENTRES OF EXCELLENCE FOR PATHOLOGICAL DIAGNOSIS

Experience in the observation of prophylactic gastrectomies for HDGC is quite limited in most pathology departments due to the rarity of these surgical specimens. Additionally, the routine workload of most centres is incompatible with the detailed observation of hundreds of sections as those obtained after total

---

**Figure 3** (A) In situ signet ring cell carcinoma: gland with intact basement membrane lined by signet ring cells, with hyperchromatic and depolarised nuclei. (B) Pagetoid spread of signet ring cells below the preserved epithelium of one gland (arrow heads). (C) Focus of invasive intramucosal carcinoma T1a, constituted by signet ring cells (arrows), in the lamina propria.

**Figure 4** (A) Foveolar hyperplasia (between arrows); in comparison to normal epithelium (below) cells are globoid (rounded with abundant cytoplasm). (B) Vacuolisation of the cytoplasm of superficial and foveolar cells. (C) Granulomatous reaction at the periphery of a disrupted gland.
In the setting of HDGC, a few tumours have been analysed for second hit inactivation mechanisms. Although somatic mutations of CDH1 do occur, promoter hypermethylation appears to be the most frequent second hit mechanism. Recently, it was shown that the second hit in CDH1 may be different in primary tumours and metastases, epigenetic changes (promoter hypermethylation) being more frequent in HDGC primary tumours and LOH in metastases. A thorough analysis of the mechanisms responsible for the second hit inactivation of CDH1 in the very early lesions of HDGC is necessary to define strategies for chemoprevention.

Alterations in other tumour suppressor genes and oncogenes are expected to play a role in the pathophysiology of HDGC, although this issue has rarely been explored in the literature. Humar et al have described that diffuse gastric cancer initiation seems to occur at the proliferative zone of the gastric epithelium and correlates with absent or reduced expression of junctional proteins. Moreover, these authors suggest that progression is associated with poor differentiation, increased proliferation, activation of the c-Src system, and epithelial–mesenchymal transition. It remains to be seen if c-Src kinase activation marks the development of early diffuse gastric cancer. Identification of the molecular mechanisms underlying disease progression is mandatory to explain why some early intramucosal carcinomas remain indolent for undefined periods of time, while others progress to higher stage, clinically significant gastric cancer.

In summary, everyone at the workshop was in agreement that there should be a group of centres caring for these patients throughout the world and we should have a system to collate data centrally using website resources, for example. For a rare condition with such profound implications for the families affected, it is essential that clinical experiences and research progress are combined in order to benefit patient management.

Author affiliations
1MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK
2Department Gastroenterology, Addenbrooke’s Hospital, Cambridge, UK
3Cambridge NIHR Biomedical Research Centre, University of Cambridge NHS Foundation Trust
4Department Gastro-Endoscopy, Addenbrooke’s Hospital, Cambridge, UK
5British Columbia Cancer Agency, Vancouver, Canada
6Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Medical Faculty of Porto/Hospital S. João, Porto, Portugal
7Biochemistry Department, University of Otago, New Zealand
8Gl Cancer Genetics Clinic, Gastrointestinal Unit, Massachusetts General Hospital, Boston
9Division of General Surgery, Stanford University, USA
10Wolfson Digestive Diseases Centre, Queens Medical Centre, Nottingham University Hospitals NHS Trust
11Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
12Cancer Research UK Familial Gastric Cancer Study, University Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
13Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre

Author footnote
These guidelines are the result of consensus statements agreed during the seventh workshop of the International Gastric Cancer Linkage Consortium (IGCLC) held on 20-21 November 2008 at the Cambridge Research Institute, Cambridge UK 2008 Workshop participants: Mr William Allum, Consultant Upper GI Surgeon, Royal Marsden Hospital, London, UK; Mr Stephen Attwood, Consultant Upper GI and Laparoscopic Surgeon, Northumbria Healthcare Trust, UK; Dr Vanessa Blair, Surgical Research Fellow, University of Otago, New Zealand; Nicola Bradshaw, MacMillan Cancer Genetic Counsellor, Glasgow, UK; Dr Carole Brewer, Consultant in Clinical Genetics, Royal Devon & Exeter Hospital, UK; Prof. Carlos Caldas, Professor of Cancer Medicine, CR UK Cambridge Research Institute, UK; Prof. Fatima Carneiro, Professor of Pathology, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Medical Faculty of Porto/Hospital S. João, Porto, Portugal; Dr Annemieke Cats, Head of Department of Gastroenterology and Hepatology.
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Pieterburen, Amsterdam, The Netherlands; Dr Amanda Charlton, Hon. Senior Clinical Lecturer, Faculty Medical and Health Sciences, Imoover of Auckland, New Zealand; Daniel C. Chung MD, Director, GI Cancer Genetics Clinic, Gastrointestinal Unit, Massachusetts General Hospital, Boston; Associate Professor in Medicine, Harvard Medical School, USA; Dr Trevor Cole, Genetist, Birmingham Women’s Hospital, Edgbaston, Birmingham, UK; Dr Gianni Corso, Department of General Surgery and Surgical Oncology, University of Siena, Italy; Prof. Jean Crabtree, Professor of Experimental Pathology, Leeds Institute Molecular Medicine, University of Leeds, UK; Dr Huw Dorkins, Consultant Geneticist, The Kennedy-Galton Centre, Harrow, UK; Sarah Dowling, Genetic Counsellor, Addenbrooke’s Hospital, Cambridge, UK; Dr Jason Dunn, Research Fellow, UCHL, London, UK; Sarah Dwyerhouse, Co-ordinator, Cancer Research UK Familial Gastric Cancer Study, UK; Dr Peter Fairclough, Consultant Gastroenterologist, Barts and the London NHS Trust, Cambridge, UK; Dr Rebecca Fitzgerald, Research UK Familial Gastric Cancer Study, UK; Dr Peter Fairclough, Consultant Pathology, Leeds Institute Molecular Medicine, University of Leeds, UK; Dr Huw O’Kane, Oncology, University of Siena, Italy; Prof. Jean Crabtree, Professor of Experimental Pathology, Massachusetts General Hospital, Boston; Associate Professor in Medicine, Harvard Medical School, USA; Dr Amanda Charlton, Hon. Senior Clinical Lecturer, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Dr Laetiitia Huart, Department of Oncogenetics, Institut Paoli-Calmettes, Marseille, France; Prof. David Huntsman, British Columbia Cancer Agency, Vancouver, and Cambridge) workshop of the International Gastric Cancer Linkage Consortium (IGCCLC) in Amsterdam, the Netherlands; Dr Matthew Wallis, Consultant Upper GI Surgeon, Cambridge, UK; Prof. Nicoline Hallissey, Consultant in General Surgery, Queen Elizabeth Hospital, Birmingham, UK; Programme Leader & Hon. Consultant Gastroenterologist, Cambridge, UK; Dr James Going, Senior Lecturer, Pathology, Glasgow Royal Infirmary, UK; Samantha Grimes, Dietitian, Addenbrooke’s Hospital, Cambridge, UK; Prof. Parry Guiffrid, Associate Professor, Cancer Genetics Laboratory, University of Otago, New Zealand; Mr Mike Hallissey, Consultant in General Surgery, Queen Elizabeth Hospital, Birmingham, UK; Ms Katrina Isaac, Consultant in Surgical Oncology, University of Sydney, Australia; Dr Richard Hardwick, Consultant Upper GI Surgeon, Cambridge, UK; Prof. Nicole Hoogerbrugge, Ph molecular basis of hereditary cancer, Associate Professor and Head of Hereditary Cancer Clinic, Radboud University Nijmegen Medical Centre, The Netherlands; Dr Laetiitia Huart, Department of Oncogenetics, Institut Paoli-Calmettes, Marseille, France; Prof. David Huntsman, British Columbia Cancer Agency, Vancouver, Canada; Dr Gisela Keller, Institute of Pathology, Munich, Germany; Dr Ann Kershaw, Consultant Genetic Counsellor, Addenbrooke’s Hospital, Cambridge, UK; Dr Aijth Kumar, Consultant in Clinical Genetics, Great Ormond Street Hospital, London, UK, Dr Laura Vernot, Consultant Gastroenterologist, Imperial College London, London, UK; Dr Ken McColl, Head of Division of Gastroenterology, Gardner Institute, Glasgow, UK; Dr Shane McKee, Consultant Clinical Geneticist, Belfast City Hospital, UK; Dr Jeffrey Norton, Professor of Surgery, Stanford University, USA; Dr Maria O’Donovan, Pathologist, Addenbrooke’s Hospital, Cambridge, UK; Dr Carla Oliveira, Research Scientist, IPATIMUP, Portugal; Dr Sylvianne Olschewski, Geneticist, Department of Molecular Oncology, Institut Paoli-Calmettes, Marseille, France and INSERM U881 Centre de Recherche en Cancérologie de Marseille, France; Mr Bijendra P Patel, Clinical Senior Lecturer and Consultant Upper GI Surgeon, Director of Surgical Skills Unit, Barts and the Royal London Hospital NHS Trust, UK; Dr Joan Paterson, Consultant, Clinical Genetics, Cambridge, UK; Dr Corrado Pedrazzani, Clinical-Research Senior Fellow in Surgical Oncology, Department of Human Pathology and Oncology, Unit of Surgical Oncology, University of Siena, Italy; Dr Paul Pharoah, Genetic Epidemiologist, Cambridge, UK; Dr Krish Ragunath, Associate Professor in Endoscopy, Wolfson Digestive Diseases Centre, Queens Medical Centre, Nottingham University Hospitals NHS Trust, UK; Dr Franco Roviello, Associate Professor of Surgery, Department of General Surgery and Surgical Oncology, University of Siena, Italy; Dr Vicki Save, Consultant Histopathologist, Royal Infirmary of Edinburgh, UK, for her role in the development of the IGCCLC in Amsterdam, the Netherlands; Dr Laetiitia Huart, Department of Oncogenetics, Institut Paoli-Calmettes, Marseille, France; Dr Francesca Sartor, Consultant Radiologist, Addenbrooke’s Hospital, Cambridge, UK; Dr Debrah Wirtzfeld, Head, Surgical Oncology, CancerCare Manitoba, Associate Professor of Surgery, Oncology and Community Health Sciences, University of Manitoba, Canada. The workshop participants wish to thank Christine Fox for secretarial support and for all travel and accommodation arrangements.

Acknowledgements The 7th (Cambridge, Vancouver, Porto, Munich, Siena, Seoul, and Cambridge) workshop of the International Gastric Cancer Linkage Consortium was made possible by generous sponsorship from the British Society of Gastroenterology.

Funding Other funders: British Society of Gastroenterology; Cancer Research UK.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Corrections

Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771–4. This paper contained some inconsistencies and errors in the TP53 gene mutation annotation. The correctly annotated mutations are shown in the revised table 1 below and are also available via the latest update of the IARC website at http://www-p53.iarc.fr/ The conclusions drawn in the paper are not altered by these mutation nomenclature errors.

Table 1 Tumour features of patients in the TP53 cohort

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at onset</th>
<th>ER</th>
<th>PR</th>
<th>HER</th>
<th>IHC (FISH)</th>
<th>Grade</th>
<th>TP53 mutation</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>35</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>3</td>
<td>c.672+1G→T</td>
<td>Truncating</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>26</td>
<td>−</td>
<td>−</td>
<td>2+ (amplified)</td>
<td>3</td>
<td>c.112C→T (p.O38X)</td>
<td>Truncating</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>24</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>3</td>
<td>c.724T→C (p.C242*)</td>
<td>Missense</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>−</td>
<td>−</td>
<td>3+</td>
<td>3</td>
<td>c.743G→A (p.R248Q)</td>
<td>Missense</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>C (31)</td>
<td>−</td>
<td>−</td>
<td>3+</td>
<td>3</td>
<td>As above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>28</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>3</td>
<td>c.659A→G (p.Y220C)</td>
<td>Missense</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>28</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>(normal range)</td>
<td>As above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>28</td>
<td>−</td>
<td>−</td>
<td>3+</td>
<td>3</td>
<td>c.625A→T (p.R209X)</td>
<td>Truncating</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>29</td>
<td>−</td>
<td>−</td>
<td>3+</td>
<td>3</td>
<td>c.919+1G→A</td>
<td>Truncating</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>24</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>3</td>
<td>c.586C→T (p.R196X)</td>
<td>Truncating</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>27</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>2</td>
<td>As above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>22</td>
<td>+</td>
<td>+</td>
<td>3+</td>
<td>3</td>
<td>c.437G→A (p.W146X)</td>
<td>Truncating</td>
<td></td>
</tr>
</tbody>
</table>

*Reported as somatic mutation 13 times and germline once, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
†Reported in 340 tumours and as causative mutation in 6 LFS families, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
C, Contralateral tumour; ER, Oestrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2; IHC, Immunohistochemistry; FISH, Fluorescent In-Situ Hybridisation.

J Med Genet 2011;48:216. doi:10.1136/jmg.2010.087113corr1

Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47:456–44. The name of one of the co-authors was misspelled in the author list of this paper and should read Van Grieken NC.

J Med Genet 2011;48:216. doi:10.1136/jmg.2009.074237corr1